Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Health Res Policy Syst ; 18(1): 11, 2020 Jan 28.
Article in English | MEDLINE | ID: mdl-31992320

ABSTRACT

BACKGROUND: Disproportionate regulation of health and medical research contributes to research waste. Better understanding of exemptions of research from ethics review in different jurisdictions may help to guide modification of review processes and reduce research waste. Our aim was to identify examples of low-risk human health and medical research exempt from ethics reviews in Australia, the United Kingdom, the United States and the Netherlands. METHODS: We examined documents providing national guidance on research ethics in each country, including those authored by the National Health and Medical Research Council (Australia), National Health Service (United Kingdom), the Office for Human Research Protections (United States) and the Central Committee on Research Involving Humans (the Netherlands). Examples and types of research projects exempt from ethics reviews were identified, and similar examples and types were grouped together. RESULTS: Nine categories of research were exempt from ethics reviews across the four countries; these were existing data or specimen, questionnaire or survey, interview, post-marketing study, evaluation of public benefit or service programme, randomised controlled trials, research with staff in their professional role, audit and service evaluation, and other exemptions. Existing non-identifiable data and specimens were exempt in all countries. Four categories - evaluation of public benefit or service programme, randomised controlled trials, research with staff in their professional role, and audit and service evaluation - were exempted by one country each. The remaining categories were exempted by two or three countries. CONCLUSIONS: Examples and types of research exempt from research ethics reviews varied considerably. Given the considerable costs and burdens on researchers and ethics committees, it would be worthwhile to develop and provide clearer guidance on exemptions, illustrated with examples, with transparent underpinning rationales.


Subject(s)
Biomedical Research/ethics , Ethics Committees, Research/organization & administration , Health Services Research/ethics , Research Design , Australia , Efficiency , Ethics Committees, Research/standards , Guidelines as Topic/standards , Humans , Netherlands , Public Health , Risk Assessment , United Kingdom , United States
2.
Ned Tijdschr Geneeskd ; 159: A9458, 2015.
Article in Dutch | MEDLINE | ID: mdl-26469735

ABSTRACT

The use of patient histories has become an essential part of medical education. Patient histories are important for the relevance, effectiveness and appeal of medical education. The sharing of patient-related information in education and further training is expected to increase in the coming years. The sharing of patient information with colleagues, students or other interested parties can conflict with the rules protecting patient privacy. The most important rule in this context is that it is the patients who decide whether their cases can be shown to others for educational purposes. Patient consent is not required if the data or images used have been fully anonymized. If the information can be traced to the patient, consent is required, preferably documented in writing. The teaching physician is responsible for the storage, protection and destruction of patient data and for controlling access to information.


Subject(s)
Confidentiality/standards , Education, Medical/methods , Privacy , Access to Information , Humans , Informed Consent
3.
Ned Tijdschr Geneeskd ; 156(40): A4603, 2012.
Article in Dutch | MEDLINE | ID: mdl-23031234

ABSTRACT

When all standard care options are exhausted, it may be justifiable to carry out an experimental treatment. In the Netherlands, experimental treatment is distinguished from medical research; the latter primarily serves the public interest (obtaining medical knowledge), while the former does not. In experimental treatment, it is a doctor's duty to explain the treatment to the patient carefully and to obtain the patient's explicit consent. In addition, the doctor needs to list all relevant aspects of the treatment in the patient's medical record. A medical practitioner who abides by these rules has acted in accordance with the Dutch law. But, given the sometimes highly risky nature of experimental treatments, is this enough? We do not think so and therefore argue for two additional conditions which are focused on transparency. First, there is a need for a service to ensure that experimental treatments are registered. Second, the effects and side effects of each experimental treatment should be reported. We envision the further elaboration of these conditions to be not only a task for the medical profession but possibly also for government-appointed institutions.


Subject(s)
Legislation, Medical , Quality of Health Care , Therapies, Investigational/standards , Biomedical Research , Humans , Netherlands , Therapies, Investigational/adverse effects
4.
Ned Tijdschr Geneeskd ; 153: A600, 2009.
Article in Dutch | MEDLINE | ID: mdl-19785803

ABSTRACT

Registration of an individual's ethnicity is, in the light of the potential risks of stigmatization and discrimination, rightfully considered a sensitive issue. Traditionally, privacy legislation offers special legal protection in the collection, registration etc. of data relating to race and ethnic background. However, if it can be established that registration of ethnicity is necessary for providing good care, registration is lawful. However, registration for health research purposes requires the explicit consent of the persons involved.


Subject(s)
Ethnicity , Patient Care/standards , Registries , Humans , Informed Consent , Minority Groups , Netherlands
SELECTION OF CITATIONS
SEARCH DETAIL
...